<DOC>
	<DOCNO>NCT02580877</DOCNO>
	<brief_summary>The study 2 arm , multi-center , randomize , open-labeled clinical trial design assess effect vary dos schedule oral insulin immunological metabolic marker relatives risk type 1 diabetes ( T1D ) .</brief_summary>
	<brief_title>Immune Effects Oral Insulin Relatives Risk Type 1 Diabetes Mellitus ( TN20 )</brief_title>
	<detailed_description>A minimum 40 eligible participant identify study participation TrialNet Pathway Prevention study . Participants must relative type 1 diabetes positive insulin autoantibody least one autoantibody . All participant receive active treatment recombinant insulin treatment capsule either 67.5 mg daily 500mg every week . Participants need visit study site eleven time one year blood test study procedure . During begin treatment phase two visit one month apart give 67.5 mg dose , three visit two week apart titrate dose 500mg treatment group . There three additional treatment visit month 2 , 3 , 6 4 additional visit follow-up month 7 , 8 , 9 12 . The primary outcome change immune function assess change level quality T lymphocyte autoantibody biomarkers measure 13 26 week compare baseline . .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<criteria>Participants TrialNet Natural History/Pathway Prevention Study ( TN01 ) ; relative proband type 1 diabetes Between age 345 normal Oral Glucose Tolerance Test ( OGTT ) age 37 abnormal OGTT Confirmed positive insulin autoantibody within previous six month Confirmed positive one autoantibodies two separate occasion within past six month Diagnosed type 1 diabetes History treatment insulin oral hypoglycemic agent History therapy immunosuppressive drug nonphysiologic glucocorticoid within past two year period three month Ongoing use medication know influence glucose tolerance Pregnant intending become pregnant study lactate</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>oral insulin</keyword>
</DOC>